Kinaset Therapeutics to Present Phase 1 Results of Frevecitinib for Asthma and COPD at ERS Congress

Kinaset Therapeutics, a clinical-stage biopharmaceutical company, is actively developing inhaled treatments for serious respiratory conditions. The company has recently unveiled its participation in the 2024 European Respiratory Society (ERS) Congress, scheduled from September 7-11 in Vienna, Austria. During this event, Kinaset will showcase two oral presentations and a late-breaking poster presentation, emphasizing the potential of its leading clinical candidate, frevecitinib (KN-002), for treating moderate to severe asthma and COPD (Chronic Obstructive Pulmonary Disease).

The leadership team at Kinaset Therapeutics, including co-founder and CEO Robert Clarke, PhD, co-founder and Chief Development Officer Frazer Morgan, and Chief Medical Officer Christopher O’Brien, MD, PhD, will be attending the conference. They aim to engage with other industry leaders and partners to discuss their advancements in respiratory disease treatments. Dave Singh, MD, Professor at the University of Manchester, who also serves as the Principal Investigator and a scientific advisor to Kinaset, will be responsible for delivering the oral presentations.

Detailed Presentation Information:

Oral Presentations:

1. Title: KN-002 reduces fractional exhaled nitric oxide in moderate to severe asthma
- Session: Airway diseases therapeutics: novel research studies
- Date and Time: Monday, September 9, 9:30 to 10:45
- Presenter: Dave Singh, MD, Professor at the University of Manchester
- Location: Lehar 3

2. Title: Safety and PK of KN-002 in subjects with moderate to severe asthma using ICS/LABA
- Session: Recent advances in biological treatments for asthma and chronic obstructive pulmonary disease
- Date and Time: Monday, September 9, 14:15 to 15:30
- Presenter: Dave Singh, MD, Professor at the University of Manchester
- Location: A1

Late Breaking Poster Presentation:

- Title: The safety and PK of an inhaled pan JAK inhibitor (KN-002) in subjects with COPD
- Session: Biological treatments for asthma: novel real-world and clinical studies
- Date and Time: Tuesday, September 10, 8:00-9:30
- Location: PS-11, Board 18

About Frevecitinib

Frevecitinib, designated by the United States Adopted Name (USAN) Council and the World Health Organization (WHO), is Kinaset’s forefront drug candidate, known as KN-002. This medication is a novel and potent inhibitor of all Janus kinase (JAK) isoforms (JAK1, JAK2, JAK3, and TYK2) and is under development as a non-invasive anti-inflammatory treatment. It aims to assist patients with eosinophilic and non-eosinophilic asthma who do not respond adequately to medium- to high-dose ICS/LABA maintenance treatment, as well as those with COPD.

Frevecitinib is formulated as a dry powder, allowing for efficient delivery. This formulation enables the administration of pharmacologically active doses through a single capsule, which achieves therapeutic drug concentrations in lung tissues while minimizing systemic exposure. The Phase 1 clinical study (NCT05006521) involving 49 healthy volunteers, 55 subjects with mild or moderate to severe asthma, and 13 subjects with COPD has been successfully completed. The company plans to initiate a Phase 2b clinical study in 2025, focusing on patients whose asthma is not adequately controlled with medium to high dose ICS/LABA.

About Kinaset Therapeutics, Inc.

Kinaset Therapeutics is dedicated to developing inhaled treatments to meet significant unmet medical needs in respiratory diseases. Backed by founding investors 5AM Ventures, Atlas Venture, and Gimv, the company adopts a patient-focused approach to establishing itself as a leading entity in respiratory therapeutics.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!